5'-O-(Elaidoyl) 1-β-D-arabinofuranosylcytosine
| Title | Journal |
|---|---|
| Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. | Investigational new drugs 20121001 |
| Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. | British journal of haematology 20120901 |
| Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. | Leukemia 20120701 |
| Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. | Leukemia research 20120401 |
| Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia. | Expert opinion on investigational drugs 20111201 |
| A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. | Cancer chemotherapy and pharmacology 20111101 |
| Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. | Current medicinal chemistry 20110101 |
| The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. | Nucleosides, nucleotides & nucleic acids 20100601 |
| Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells. | Nucleosides, nucleotides & nucleic acids 20100601 |
| Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. | International journal of oncology 20100101 |
| Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. | Acta oncologica (Stockholm, Sweden) 20090101 |
| CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. | British journal of haematology 20090101 |
| Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. | Leukemia & lymphoma 20080401 |
| Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. | Biochemical pharmacology 20040201 |